Inovio Pharmaceuticals Inc
INO
查看详细走势图
2.335USD
+0.055+2.41%
交易中 （美东）报价延迟15分钟
125.09M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.41%
5天
+13.35%
1月
+32.67%
6月
+19.13%
今年开始到现在
+27.60%
1年
+26.90%
查看详细走势图
TradingKey Inovio Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Inovio Pharmaceuticals Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名107/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.63。中期看，股价处于平稳状态。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Inovio Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
7.633
目标均价
+265.23%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Inovio Pharmaceuticals Inc亮点
亮点风险
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
业绩增长期
公司处于发展阶段，最新年度总收入217.76K美元
估值低估
公司最新PE估值-0.84，处于3年历史低位
机构减仓
最新机构持股11.15M股，环比减少30.15%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值3.03K
Inovio Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Inovio Pharmaceuticals Inc简介
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
公司代码INO
公司Inovio Pharmaceuticals Inc
CEOShea (Jacqueline Elizabeth)
网址https://www.inovio.com/
常见问题
Inovio Pharmaceuticals Inc(INO)的当前股价是多少？
Inovio Pharmaceuticals Inc(INO)的当前股价是 2.335。
Inovio Pharmaceuticals Inc的股票代码是什么？
Inovio Pharmaceuticals Inc的股票代码是INO。
Inovio Pharmaceuticals Inc股票的52周最高点是多少？
Inovio Pharmaceuticals Inc股票的52周最高点是2.979。
Inovio Pharmaceuticals Inc股票的52周最低点是多少？
Inovio Pharmaceuticals Inc股票的52周最低点是1.300。
Inovio Pharmaceuticals Inc的市值是多少？
Inovio Pharmaceuticals Inc的市值是125.09M。
Inovio Pharmaceuticals Inc的净利润是多少？
Inovio Pharmaceuticals Inc的净利润为-107.25M。
现在Inovio Pharmaceuticals Inc(INO)的股票是买入、持有还是卖出？
根据分析师评级，Inovio Pharmaceuticals Inc(INO)的总体评级为买入，目标价格为7.633。
Inovio Pharmaceuticals Inc(INO)股票的每股收益（EPS TTM）是多少
Inovio Pharmaceuticals Inc(INO)股票的每股收益（EPS TTM）是-2.717。
相关品种
